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a b s t r a c t
In the continued absence of an effective anti-HIV vaccine, approximately 2 million new HIV infections
occur every year, with over 95% of these in developing countries. Calls have been made for the devel-
opment of anti-HIV drugs that can be formulated for topical use to prevent HIV transmission during
sexual intercourse. Because these drugs are principally destined for use in low-resource regions,
achieving production costs that are as low as possible is an absolute requirement. 5P12-RANTES, an
analog of the human chemokine protein RANTES/CCL5, is a highly potent HIV entry inhibitor which acts
by achieving potent blockade of the principal HIV coreceptor, CCR5. Here we describe the development
and optimization of a scalable low-cost production process for 5P12-RANTES based on expression in
Pichia pastoris. At pilot (150 L) scale, this cGMP compliant process yielded 30 g of clinical grade 5P12-
RANTES. As well as providing sufficient material for the first stage of clinical development, this pro-
cess represents an important step towards achieving production of 5P12-RANTES at a cost and scale
appropriate to meet needs for topical HIV prevention worldwide.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
There is an urgent need for new products that can be used to
stem the spread of HIV/AIDS, particularly in developing countries,
where over 95% of the estimated 2 million new infections per year
occur [1]. Among the strategies being explored are those centered
on the use of topically applied anti-HIV drugs, which can be used to
prevent transmission of the virus during sexual intercourse [2].
Blockade of the principal HIV coreceptor, CCR5, is a highly
promising strategy for topical HIV prevention [3,4]. Analogs of
the natural chemokine protein ligands of CCR5, including RANTES/
CCL5, have potential use as agents for topical HIV prevention
[5e7]. PSC-RANTES was the first chemokine analog to show not
only high potency in vitro against HIV strains [8] but also full effi-
cacy in a highly stringent and relevant animal model of HIV
transmission [5]. However, since it contains non-natural structures
that require chemical synthesis steps, PSC-RANTES was considered
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too expensive to produce for its intended use in resource-poor
settings [9].
5P12-RANTES [7] is a next-generation fully recombinant analog
which was developed using a phage display approach [10]. In
addition to having potency and efficacy comparable to that of PSC-
RANTES [7,11], 5P12-RANTES shows promising stability under
storage at elevated temperature and also when exposed to vaginal
pH, human cervicovaginal lavage and human semen [12]. Impor-
tantly, it has also been shown to present a formidable barrier to the
generation of escape mutants [13]. Hence 5P12-RANTES represents
a highly promising candidate for development as a topical agent for
HIV-prevention.
In order to identify an appropriate recombinant expression
system for large scale low cost production of 5P12-RANTES, we
focused on yeast secretory expression, which has been shown to be
robust and effective for other chemokines [14e16], including ana-
logs of RANTES/CCL5 [17,18]. In this study we made use of expres-
sion in Pichia pastoris (formally classified as Komagataella phaffii
[19]) to develop and optimize of a low-cost, scalable cGMP-
compliant process for production of clinical grade 5P12-RANTES
(i.e. >95% purity; endotoxin, host cell protein and host cell DNA
levels within regulatory limits).
2. Materials and methods
2.1. Chemically synthesized reference standard 5P12-RANTES
5P12-RANTES was synthesized as described previously [7] on a
modified ABI 430 peptide synthesizer customized to perform Boc
chemistry with in situ neutralization [20]. The synthesis strategy
featured a chemical capping step (to terminate any chains with free
amine groups at the end of the coupling step) using acetylglycine at
each cycle. After hydrogen fluoride cleavage, crude product was
analyzed by reverse-phase HPLC and MALDI mass spectrometry.
After preparative scale purification of the desired product, refolding
of the protein and formation of disulphide bridges was carried out
according to published procedures [21], and the refolded material
was verified by reverse-phase HPLC (shorter retention time) and
electrospraymass spectrometry (loss of mass units due to oxidation
of cysteine thiol group during disulphide bridge formation). A final
preparative scale purification was performed on the refolded ma-
terial, which was then lyophilized prior to use.
2.2. Determination of anti-HIV activity
Anti-HIV activities of samples were determined using a CCR5-
tropic envelope-dependent cell fusion assay as previously
described [7,8].
2.3. Pilot process
2.3.1. Strain for pilot work
A synthetic gene encoding 5P12-RANTES [7] was synthesized
(Integrated DNA Technologies) and ligated as an in-frame fusion
directly after the KREAEA sequence of the alpha mating factor
encoded by the pJAZaMF expression vector [22] (Biogrammatics),
which carries the Alcohol Oxidase 1 (AOX1) promoter, allowing
inducible expression on methanol. This vector was then linearized
at the PmeI site in the AOX1 promoter and transformed into the
P. pastoris strain Bg08 (Biogrammatics). Zeocin-selected clones
were isolated and assessed for expression of 5P12-RANTES.
2.3.2. ELISA assay for quantification of 5P12-RANTES levels
Because of the sequence similarities between 5P12-RANTES and
native human RANTES/CCL5, it was possible to set up an ELISA
detection assay for 5P12-RANTES using a pair of commercially
available antibodies sold as components of a kit for detecting levels
of native RANTES/CCL5 (MAB678 for capture, BAF278 for detection,
R&D Systems). The assay was performed according to the manu-
facturer's instructions, except that standard curves were prepared
using 5P12-RANTES rather than native CCL5. The assay provided a
linear detection range for 5P12-RANTES concentrations between
0.063 ng/mL and 2 ng/mL. Samples of culture supernatant were
subjected to a range of dilutions and used as test samples in the
ELISA assay, with concentrations of 5P12-RANTES estimated by
back-calculating from the resulting absorbance values.
2.3.3. Cation exchange chromatography
Cation exchange chromatography was carried out using a
Varian chromatography system on a 11  1 cm SP Sepharose Fast
Flow column (Amersham Pharmacia) equilibrated with 10 column
volumes of 50 mM Bicine buffer pH 7.5. 15 mL of P. pastoris culture
supernatant was pH adjusted to 8.5 with triethylamine, centri-
fuged (18000 g, 5 min), and loaded in successive 1 mL injections.
Separation was achieved by applying a gradient of 0e2 M NaCl in
50 mM Bicine buffer pH 7.5 over 30 min with a flow rate of 1 mL/
min.
2.3.4. Reverse phase chromatography (RP-HPLC)
Semi-preparative RP-HPLC was carried out using a Waters 2795
HPLC Separation Module with a 2487 Dual l Absorbance Detector.
The 15 mL eluate peak collected from the cation chromatography
step was diluted with 15 mL of 0.1% TFA, acidified with 0.4 mL of
glacial acetic acid and passed through 1 mL C18 Sep-Pak cartridges
(WAT051910,Waters) that had been pre-equilibratedwith 0.1% TFA.
Cartridges were then washed with 20 mL of 0.1% TFA and eluted
with 4 mL of 0.1% TFA: acetonitrile, 1:1 (v/v). The eluates from the
cartridges were pooled, dried, and taken up in 50% acetonitrile/0.1%
TFA. 20 ml samples were injected on to aMachereyeNagel 300 Å mm
C8 column (250  4 mm) and a gradient (22.5%e49.5% acetonitrile
in 0.1% TFA) was applied over 30minwith a flow rate of 0.7 ml/min.
2.3.5. Mass spectrometry
Masses of samples purified by reverse phase HPLC were deter-
mined on a Platform LCZ (Micromass) electrospray positive ioni-
zation mass spectrometer. Mass spectra were acquired and
analyzed using MassLinx software.
2.4. Scaled-up process
2.4.1. Strain for cGMP-compliant production of clinical grade
material
A fully synthetic construct containing codon-optimized 5P12-
RANTES open reading frame (ORF) fused ineframe with the
Saccharomyces cerevisiae alpha mating factor was synthesized
(GeneArt, LifeTechnologies). This construct was flanked with a 50
EcoRI and a 30 NotI-restriction site for cloning into the pPpT4aS-
expression vector (Graz University of Technology, TU Graz). The
final pPpT4aMF-5P12-RANTES expression vector carries a Zeocin®
selection marker with 5P12-RANTES-expression under control of
the AOX1 promoter. All cloning was done using TSE/BSE-free
certified restriction enzymes (New England Biolabs).
The pPpT4aMF-5P12-RANTES vector was PmeI-linearized in the
AOX1-promoter prior to electroporation to the P. pastoris NRRL Y-
11430 strain. Zeocin-selected clones were isolated and assessed for
expression of 5P12-RANTES. The best-expressing clone, was taken
through a standard cell banking procedure.
2.4.2. Screening for 5P12-RANTES expression
Single clones were used to inoculate 2 mL BMGY medium (1%
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yeast extract, 2% Soy Peptone, 100 mM potassium phosphate buffer
pH 5.5, 1.34% Yeast Nitrogen Base, 1% glycerol) in 24-well deep well
plates and incubated at 28 C and 225 rpm for 48 h. The cells were
harvested by centrifugation (265 g, 10 min, 4 C) and taken up in
2 mL unbuffered BMY medium (1% yeast extract, 2% Soy Peptone,
1.34% Yeast Nitrogen Base). Prior to induction, the culture was
acidified to pH 3.5 using 1 M citric acid. The cultures were induced
with methanol (1% final, v/v) and induction was maintained by
spiking the cultures every 8e12 h with an additional 1% MeOH.
After induction, the supernatant was collected by centrifugation
(265 g, 10 min, 4 C), snap-frozen in liquid nitrogen and kept
at 20 C until further analysis.
2.4.3. In-process detection of 5P12-RANTES using strong cation
exchange HPLC
Levels of 5P12-RANTES could be determined directly from
fermentation and in-process samples using strong cationic ex-
change chromatography (SCX). A PolySULFOETHYL A column
(PolyLC, Inc; 100  4.6 mm) operating with a flow rate of 1 mL/min
was equilibrated with Buffer A (50 mM 2-(N-morpholino)ethane-
sulfonic acid (MES), pH 6.4). Following sample application, the
following gradient was applied: 2 mine8 min; 0%e30% Buffer B
(50 mM MES, 1 M NaCl, pH 6.4), 8 mine40 min 30%e55% Buffer B,
40 mine43 min; 55%e100% Buffer B. Eluted protein was detected
by measuring absorbance of at 280 nm. Using this method 5P12-
RANTES with the N-terminal glutamine residue cyclized to pyro-
glutamate elutes after approximately 14 min, and 5P12-RANTES
with the N-terminal glutamine residue uncyclized elutes after
approximately 15 min. The method has a linear range from 0.25 to
300 mg.
2.4.4. Analytical RP-HPLC for final assessment of purity
Analytical RP-HPLC was performed on an Alliance HPLC system
with a 4.6 mm  150 mm 300 Å 3 mm C8 column (ACE), using
mobile phases A (0.1% TFA in water), B (0.0955% TFA/30% acetoni-
trile in water) and C (0.085% TFA/95% acetonitrile in water). Flow
ratewas 1mL/min. Following sample loading, the gradient program
shown in Table 1 was applied.
2.5. 19 L Scale process
2.5.1. Fermentation
A 1 L baffled shake flask containing 300 mL of buffered minimal
glycerol yeast extract medium (12.61 g/L glycerol, 10.0 g/L yeast
extract, 20.0 g/L soytone, 1.34% YNB, 4  10-5% biotin, 100 mM
potassium phosphate, pH 6.0) was inoculated with 0.5 mL of the
working cell bank and incubated for 24e28 h at 28 C and 250 rpm
until the culture OD600 reached  5.
The shake flask culture was used to inoculate a 19 L NLF
fermenter (Bioengineering, Inc) containing 6 L of basal salts me-
dium (0.93 g/L CaSO4, 18.2 g/L K2SO4, 14.9 g/L MgSO4$7H2O, 4.13 g/L
KOH, 40.0 g/L glycerol, 26.7 mL/L of 85% H3PO4) supplemented with
4.35 mL/L PTM1 salt solution (6 g/L CuSO4$5H2O, 20.0 g/L ZnCl2,
0.08 g/L NaI, 65.0 g/L FeSO4$H2O, 3.0 g/L MnSO4$H2O, 0.020 g/L
H3BO3, 0.20 g/L Na2MoO4$2H2O, 0.50 g/L CoCl2$6H2O, 5 mL/L
H2SO4.
Fermentation was conducted at 30 C with the airflow fixed at
6 L/min and a pressure set-point of 0.20 bar. During the initial batch
phase, pH was maintained at 5.0 using 28e30% ammonium hy-
droxide and the dissolved oxygen level maintained at 40%. After
18e24 h, glycerol fed-batch growth (feeding with 20 g/L/h glycerol)
was initiated for 1 h, then the temperature was reset to 27 C and
the pH allowed to decrease to 3.25 over the course of 1 h. Culture
induction was then initiated by adding a 1 g/L bolus of methanol
and decreasing the glycerol feed from 20 g/L/h to 0 g/L/h over 3 h.
Once the culture had consumed the initial methanol bolus, meth-
anol fed-batch growth was initiated (methanol supplemented with
12 mL/L PTM1 salts and 12 mL/L 5% KFO 673 antifoam provided at
an initial rate of 0.027 mL/L/min, increased to 0.066 mL/L/min over
the course of 3 h). A ten-step methanol feed profile was then
initiated (feed rates shown in Table 2), with induction maintained
over 96 h culture.
2.5.2. Harvest by tangential flow filtration
A Model 10 tangential flow filtration (TFF) skid equipped with a
0.93 m2 regenerated cellulose 100 kDa MWCO membrane was
equilibrated with 2 L of equilibration buffer (25 mM sodium ace-
tate, pH 4.0) supplemented with 300 mM NaCl. Approximately
10.9 L of fermentation broth was pumped into the system and
concentrated to 10 L. During filtration, retentate was agitated with
an overhead mixer to prevent the cells from settling. Retentate
volume was maintained at ~10 L as the cells were washed with 4
volumes of equilibration buffer. The bulk permeate was collected
and saved for further processing.
2.5.3. Preparation of Butyl 650 M load
Approximately 40.6 L of bulk permeate was adjusted to 2.5 M
NaCl (via addition of granular NaCl) during mixing over 45 min,
with a further 15 min mixing stage appended to ensure that NaCl
dissolution was complete. The permeate was than filtered through
a 0.2 mm Supor filter (Pall).
2.5.4. Capture of 5P12-RANTES with Butyl 650 M
A 10 cm  8.5 cm Butyl 650 M column was cleaned with 1 M
NaOH for 1 h and equilibrated with equilibration buffer adjusted to
2.5 M NaCl. Filtered permeate was loaded onto the column which
was then washed with 5 column volumes equilibration buffer
adjusted to 2.5 M NaCl. Elution was performed over 10 column
volumes following a linear gradient from 100% equilibration buffer
adjusted to 2.5MNaCl to 100% equilibration buffer. A 10.9 L product
fraction was collected.
2.5.5. Capto MMC intermediate chromatography
A 6 cm  18.3 cm Capto MMC column was cleaned with 1 M
NaOH for 1 h. Following equilibration with MMC equilibration
buffer (25 mM N-cyclohexyl-3-aminopropanesulfonic acid, 25 mM
sodium acetate, 25 mM sodium phosphate, pH 4.0), the eluate from
the Butyl 650 M chromatography was loaded on to the column,
which was then washed with five column volumes of equilibration
buffer. Elution of 5P12-RANTES was achieved over a 10 column
volume linear gradient starting at 100% MMC equilibration buffer
and ending at 100% MMC equilibration buffer supplemented with
2 M NaCl and adjusted to pH 10.0. A product fraction of 7.7 L was
collected.
Table 1
Gradient program used for analytical RP-HPLC of 5P12-RANTES samples.
Time (min) % Mobile phase A % Mobile phase B % Mobile phase C
0.01 83.3 16.7 0.0
0.50 83.3 16.7 0.0
1.50 10.0 90.0 0.0
4.50 10.0 90.0 0.0
25.43 0.0 100.0 0.0
26.00 0.0 0.0 100.0
29.00 0.0 0.0 100.0
29.50 83.3 16.7 0.0
35.00 83.3 16.7 0.0
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2.5.6. pH adjustment
The Capto MMC product was pH adjusted to pH 4.0 by adding
approximately 145mL 50% acetic acid over 20min. The pH adjusted
product was stored overnight at 4 C.
2.5.7. Concentration/diafiltration
A tangential flow filtration system consisting of a positive
displacement pump (PDL-004-FILT) equipped with a 0.46 m2 U
3 kDaMWCO flat sheet membranewas equilibrated with 300mL of
diafiltration buffer (100 mM sodium phosphate buffer, pH 6.0). The
7.7 L of pH adjusted Capto MMC product was concentrated to
500 mL, and the retentate volume was maintained at 500 mL
during diafiltration (6 volumes of diafiltration buffer), which was
carried out at room temperature over 175 min. The final retentate
volume was 1.65 L (pH 5.9) after rinsing the system with
3  500 mL diafiltration buffer.
2.5.8. Cyclization of the N-terminal glutamine residue
The final retentate from the diafiltration step was diluted to
10.7 L with diafiltration buffer to reach a concentration of ~1mg/mL
and transferred to a clean NLF fermentation vessel (Bioengineering,
Inc), where it was subjected to 4 h incubation at 60 C, under gentle
agitation and N2 sparge to maintain dissolved oxygen levels
at  1.0%.
2.5.9. CHT (Ceramic Hydroxyapatite) type I 20 mm polishing
chromatography
10.5 L of N-terminal glutamine-cyclized 5P12-RANTES was
filtered through a 0.2 mm PVDF filter (Millipore) and slowly added
to ~94.5 L of CHT dilution buffer (50 mM MES, pH 6.5). The diluted
filtrate was loaded overnight at 200 mL/min on to a 10 cm  15 cm
CHT type I 20 mm column that had been equilibrated with three
column volumes of CHT equilibration buffer (50 mM MES, 5 mM
sodium phosphate, pH 6.5). The column was then washed initially
with five column volumes CHT equilibration buffer, and subse-
quently with 100 column volumes of CHTwash buffer (50mMMES,
5mM sodium phosphate, 100mM sodium chloride, pH 6.5). Elution
of 5P12-RANTES was achieved over a 30 column volume gradient
starting at 100% CHT wash buffer and ending at 100% CHT wash
buffer adjusted to 200 mM NaCl. Fractions were analyzed by RP-
HPLC for purity, with selected fractions combined to generate a
~31 L pool of purity >95%, which was stored at 4 C overnight.
2.5.10. Final concentration/diafiltration and bulking
The tangential flow filtration system used in the concentration/
diafiltration was cleaned with 0.5 M NaOH for 1 h, extensively
rinsed with posidyne-filtered reverse osmosis water, and equili-
brated with 300 mL of final bulking solution (1.7 mM acetic acid pH
4.0). The pooled CHT product was concentrated from 31 L to 400mL
and diafiltered against 8 volumes of final bulking solution. The
diafiltrate was then concentrated to the minimum volume of the
system (425 mL) and drained. The recovered material was filtered
using a 0.2 mm Supor filter (Pall) and stored at 80 C.
2.6. 150 L Scale process
2.6.1. Seed train
Two 1 L baffled shake flasks containing 300 mL of buffered
minimal glycerol yeast extract medium were inoculated with
0.5 mL of the working cell bank and incubated for 15e30 h at 28 C
and 250 rpm until the culture OD600 reached 5. 63 mL of pooled
shake flask culture was used to inoculate an ALF 903 fermenter
(New Brunswick) containing 3.36 L of buffered minimal glycerol
yeast extract medium. Fermentation was run for 8e15 h at 30 C
(cascade agitation 200e800 rpm, airflow at 4.2 L/min, dissolved
oxygen levels maintained at 40%) until the culture OD600
reached  5.
2.6.2. Fermentation
The entire seed culture was then used to inoculate a 200 L
fermenter (Bio Engineering) containing 83 L of basal salts medium
supplemented with 362.1 mL of PTM1 salt solution and 83 mL of 5%
KFO 673 antifoam. Fermentation was conducted at 30 C with the
airflow fixed at 83 standard liters per minute, agitation at
100e600 rpm. During the initial batch phase, pHwasmaintained at
5.0 using 20e30% ammonium hydroxide and the dissolved oxygen
level maintained at 40%. When glycerol in the medium was
exhausted (after 18e24 h fermentation), indicated by a dissolved
oxygen spike, glycerol fed-batch growth (feeding a total of 3.75 L
63% (w/v) glycerol containing 12 mL/L PTM1 salt solution over 4 h)
was initiated. Glycerol fed-batch consisted of a 1 h feed of 20 g/L/h
followed by a 3 h ramp down to 0 g/L/h. The temperature was then
reset to 27 C and the pH allowed to decrease to 3.25 over the
course of approximately 1 h. Inductionwas then initiated by adding
a 1 g/L bolus of methanol. Once the culture had consumed this
initial methanol bolus, methanol fed-batch growth was initiated
(methanol supplemented with 12 mL/L PTM1 salt solution and
12 mL/L 5% KFO 673 antifoam provided at an initial rate of
0.027 mL/L/min, increased to 0.066 mL/L/min over the course of
3 h). The same ten-step methanol feed profile as used in the 19 L
scale fermentation was then initiated (Table 2) with the exception
that fermentation was halted after 72 h induction.
2.6.3. Harvest by tangential flow filtration
A Model 50 tangential flow filtration (TFF) skid equipped with a
4.64 m2 regenerated cellulose 100 kDa MWCO membrane was
equilibrated with 20 L of equilibration buffer supplemented with
300mM sodium chloride. Retentate volumewasmaintained at 50 L
as the cells were washed with 4 volumes of equilibration buffer
supplemented with 300 mM sodium chloride. The bulk permeate
was collected for further processing.
2.6.4. Preparation of Butyl 650 M load
Bulk permeate was adjusted to 2.5 M NaCl (via addition of
granular NaCl) during mixing over 45 min, with a further 15 min
mixing stage appended to ensure that NaCl dissolution was com-
plete. The permeate was than 0.2 mm filtered into 200 L barrel bags
(Sartorius).
Table 2
Ten-step methanol feed profile used in scaled-up fermentation process.
Step Induction time (h) Feed rate (mL/L/min) Step Induction time (h) Feed rate (mL/L/min)
1 3.0 0.066 6 53.40 0.179
2 13.08 0.080 7 63.48 0.218
3 23.16 0.098 8 73.56 0.267
4 33.24 0.120 9 83.64 0.326
5 43.32 0.146 10 93.72 0.399
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2.6.5. Capture of 5P12-RANTES with Butyl 650 M
A 30 cm  15 cm Butyl 650 M column was equilibrated with
three column volumes of equilibration buffer supplemented with
2.5 M NaCl. The columnwas loaded with the filtered permeate and
washed with five column volumes of equilibration buffer supple-
mented with 2.5 M NaCl. Elutionwas performed by passing a linear
gradient from 100% 2.5 M NaCl in equilibration buffer to 100%
equilibration buffer over ten column volumes, followed by a hold
phase (100% equilibration buffer) until completion of elution.
2.6.6. Capto MMC intermediate chromatography
A 30 cm  15 cm Capto MMC column was equilibrated with
three column volumes ofMMC equilibration buffer. The eluate from
the Butyl 650 M chromatography step was then loaded on to the
column, which was thenwashedwith five column volumes of MMC
equilibration buffer. Elution of 5P12-RANTES was achieved over a
10 column volume linear gradient starting at 100% MMC equili-
bration buffer and ending at 100% MMC equilibration buffer sup-
plemented with 2 M NaCl and adjusted to pH 10.0.
2.6.7. Concentration/diafiltration
A Model 10 tangential flow filtration skid equipped with a
4.64 m2 regenerated cellulose 3 kDaMWCOmembranewas flushed
with 5 L of diafiltration buffer, drained and then loaded with the
MMC eluate. The retentate was collected after 15-fold concentra-
tion and diafiltration against six volumes of diafiltration buffer.
2.6.8. Cyclization of the N-terminal glutamine residue
The diafiltration retentate was diluted with diafiltration buffer
to reach a concentration of 1 mg/mL 5P12-RANTES and transferred
to a 250 L process tank, where it was subjected to 4 h incubation at
60 C, under gentle agitation and N2 sparge to maintain dissolved
oxygen levels at  1.0%. Material was diluted 20-fold into CHT
dilution buffer (50 mMMES, pH 6.5) and 0.2 mm filtered into barrel
bags (Sartorius).
2.6.9. CHT (Ceramic Hydroxyapatite) type I 20 mm polishing
chromatography
The diluted material was loaded at on to a 45 cm  11 cm CHT
type I 20 mm column that had been equilibrated with three column
volumes of CHT equilibration buffer. The column was first washed
with five column volumes CHT equilibration buffer, then with 100
column volumes of CHT wash buffer. Elution of 5P12-RANTES was
achieved over a 30 column volume linear gradient starting at 100%
CHT wash buffer and ending at 100% CHT wash buffer adjusted to
200 mM NaCl, followed by a hold phase (100% CHT wash buffer
adjusted to 200 mM NaCl) until elution was complete. Fractions
were analyzed by RP-HPLC for purity, with selected fractions
combined to generate a pool of purity >95%.
2.6.10. Final concentration/diafiltration and bulking
A Model 10 tangential flow filtration skid equipped with a
2.32m2 regenerated cellulose 3 kDaMWCOmembranewas flushed
with 2 L of final bulking solution, drained and then loaded with the
pooled CHT eluate. The retentate was collected after concentration
calculated to yield a final concentration of 8.5 g/L 5P12-RANTES and
diafiltration against eight volumes of final bulking solution.
3. Results
3.1. Pilot expression studies
Zeocin-resistant clones obtained by transforming P. pastoris
strain Bg08 with the pJAZaMF encoding 5P12-RANTES were
screened for 5P12-RANTES expression. A single clone, clone #86
(Mutþ phenotype), was selected for pilot expression in a 5 L
fermenter.
The harvested culture supernatant, untreated or following 10%
trichloroacetic acid (TCA) precipitation, was analyzed by SDS-PAGE
alongside a chemically synthesized reference standard sample of
5P12-RANTES (Fig. 1). The position of the major band from the
untreated culture supernatant on the gel with respect to the mo-
lecular mass markers and the reference standard sample was
consistent with its identity as 5P12-RANTES. Further confirmation
was obtained by Western blot using an anti-human RANTES/CCL5
antibody (data not shown). TCA precipitation of increasing volumes
of the culture supernatant did not give an increase of band in-
tensities in proportion to the volumes taken, indicating that only a
fraction of the total target protein is precipitated under these
conditions.
Using an ELISA assaywewere able to estimate the concentration
of 5P12-RANTES in the crude culture supernatant as 100 mg/L.
3.2. Lab-scale purification
We next purified the material for further characterization using
a two-step procedure. The first step, cation exchange chromatog-
raphy, takes advantage of the high isoelectric point of 5P12-RANTES
(predicted value 9.4, based on primary sequence using the Compute
pI/Mw tool (www.expasy.org)). Cation-exchange chromatography
of a 15mL sample of culture supernatant resulted in the elution of a
single major peak (Fig. 2).
An aliquot of the eluted peak material was subjected to semi-
preparative RP-HPLC (Fig. 3A), yielding a series of peaks (labeled
1 to 5 according to retention time), which were collected and
analyzed by mass spectrometry. The peak with the longest reten-
tion time (Peak 1 in Fig. 3A) had a mass corresponding to intact,
folded 5P12-RANTES (obs ¼ 7904.7 ± 0.08, expected 7904.8).
Its retention time was consistent with that of a chemically syn-
thesized reference standard sample of 5P12-RANTES loaded on
the same column on the same day (red trace in Fig. 3A). Both Peak 2
and Peak 3 (the major peak in the chromatogram), had indistin-
guishable masses (7921.6 ± 0.27), potentially corresponding to
either (i) intact folded 5P12-RANTES in which the N-terminal
glutamine residue had not yet undergone cyclization to pyroglu-
tamate (expected ¼ 7921.7), or (ii) intact folded 5P12-RANTES in
which one of the two methionine residues had been oxidized to
Met(O) (expected ¼ 7920.7). Peak 4 had a mass of 7937.6 ± 0.15,
consistent with either (i) intact folded 5P12-RANTES in which the
Fig. 1. Pilot study of 5P12-RANTES expression by secretion in P. pastoris. Coommassie
stained SDS-PAGE gel of culture supernatant from an unoptimized 5 L fermentation.
Lanes 1 and 7: molecular mass markers; Lane 2: 20 ml unpurified culture supernatant;
Lanes 3, 4 and 5: TCA precipitates of larger volumes of culture supernatant corre-
sponding to 220 ml, 450 ml and 900 ml, respectively; Lane 6: chemically synthesized
5P12-RANTES reference standard (4 mg).
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N-terminal glutamine residue had not yet undergone cyclization to
pyroglutamate and one of the two methionine residues had been
oxidized to Met(O) (expected ¼ 7937.7), (ii) intact folded 5P12-
RANTES in which the cyclization of the N-terminal glutamine
residue had occurred and both methionine residues had been
oxidized to Met(O) (expected ¼ 7937.7), or (iii) intact folded 5P12-
RANTES in which the cyclization of the N-terminal glutamine res-
idue had occurred and one of the two methionine residues had
been oxidized to Met(O2). We were unable to determine a mass for
Peak 5.
Postulating that the major peak (Peak 3 in Fig. 3A) was likely to
be 5P12-RANTES with an uncyclized N-terminal glutamine, we
took a second aliquot from material purified by cation exchange
chromatography and subjected to it conditions previously shown to
favor N-terminal glutamine cyclization [23]. The pH of the fraction
was increased to 8.5 using triethylamine and then maintained
under N2 for 64 h at 37 C prior to semi-preparative RP-HPLC
(Fig. 3B). This treatment resulted in significant reduction of the
peak with a retention time corresponding to Peak 3 in Fig. 3A and
an increase in the peak corresponding to the authentic product,
Peak 1 in Fig. 3A. We concluded that major peak from the partially
purified material was intact folded 5P12-RANTES with an uncycl-
ized N-terminal glutamine, and that it can be readily converted into
authentic product by appropriate treatment. It is likely that the
remaining peaks with shorter retention times than the target ma-
terial correspond to a mixture of (i) residual 5P12-RANTES with an
uncyclized N-terminal glutamine residue, as well as (ii) N-terminal
glutamine cyclized and uncyclized 5P12-RANTES carrying one or
two oxidized methionine residues.
RP-HPLC-purified material corresponding to Peak 1 in Fig. 3A
was tested for biological activity in a CCR5-tropic HIV envelope-
dependent cell fusion assay [7,8] (Fig. 4). The anti-HIV potency of
purified sample of recombinant 5P12-RANTES was indistinguish-
able (IC50 18 pM, 95% confidence interval 8.2e38 pM) from that of
the chemically synthesized reference sample (IC50 33 pM, 95%
confidence interval 9.4e120 pM).
In summary, without any optimization, pilot production in
P. pastoris yielded approximately 100 mg/L culture of 5P12-RANTES
which could be readily purified and shown to be authentic by RP-
HPLC retention time, mass spectrometry and biological activity.
Based on these results we opted to proceed with strain optimiza-
tion and the development of a scaled up cGMP compliant produc-
tion process to generate clinical grade material.
Fig. 2. Semi-preparative pilot purification of crude culture supernatant by cation
exchange chromatography. 15 mL Culture supernatant from the 5 L fermentation was
subjected to cation exchange chromatography on an SP Sepharose Fast Flow resin
column. The major peak (approx. 24 min) was collected for further analysis. The minor
peak (approx. 13 min) corresponded to elution of strongly pigmented material present
in the culture supernatant.
Fig. 3. RP-HPLC purification of 5P12-RANTES. Pooled material eluted from the pre-
vious cation chromatography step was subjected to semi-preparative RP-HPLC puri-
fication. A. Untreated pooled eluate (red trace: a chemically synthesized standard). B.
Pooled eluate following treatment to promote cyclization of the N-terminal glutamine
residue (pH 8.5, 37 C, 64 h). Retention times in minutes are indicated above each peak.
(For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
Fig. 4. Anti-HIV activity of the purified recombinant sample of 5P12-RANTES is
indistinguishable from that of the chemically synthesized reference standard.
Dilutions of each sample were tested in triplicate for their ability to block R5-tropic
HIV envelope-mediated cell fusion in a standard assay [7,8]. Mean and S.D. are
shown for each dilution. Dose-response curves were fitted using Prism (GraphPad).
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3.3. Scale-up and development of a process for producing cGMP-
compliant clinical grade material
3.3.1. Generation of a certified TSE-free parent strain
Since the pilot study was carried under conditions where
absence of transmissible spongiform encephalopathy (TSE) ele-
ments could not be certified, we opted to generate an entirely new
production strain, starting with the P. pastoris NRRL Y-11430 strain
(ATCC). To ensure no TSE contamination would be passed on from
this strain to the production strain, it was sub-cultured through ten
serial passages in chemically defined TSE-free certified medium
prior to engineering.
3.3.2. Construction of the 5P12-RANTES expression strain
P. pastoris NRRL Y-11430 clones transformed with the
pPpT4aMF-5P12-RANTES expression vector were isolated and
screened for 5P12-RANTES expression. The best expressing clone
(clone 17) was selected for scaled-up process development.
3.3.3. Process development strategy
Process development involved optimizing fermentation condi-
tions developing a downstream process that yields clinical grade
final product to cGMP specifications. The fermentation procedure
does not generate any environmentally harmful contaminants.
Firstly, no selection antibiotic is used during the fermentation
phase. Secondly, while methanol is used as a sole carbon source
during the induction phase of fermentation, its primary metabolite,
formaldehyde, does not accumulate as it is further metabolized by
the culture [24]. Care was taken in the design of the downstream
process to avoid steps that either (i) require expensive solvents or
resins, or (ii) would not be readily scalable. The overall process is
outlined in Fig. 5. Conditions were initially optimized at the 19 L
scale, and then scaled up to the 150 L scale.
3.3.4. Fermentation and harvest
Fermentation conditions were optimized for each stage of the
fermentation according to the following parameters: temperature,
dissolved oxygen levels, pH, carbon source feed rates. The opti-
mized fermentation protocol of 5P12-RANTES producer strain
Clone 17 at the 19 L scale, generated 419 g/L wet weight of cells and
1.60 g/L 5P12-RANTES in a total of 10.9 L culture supernatant. Two
150 L scale runs were performed, a shakedown run and a cGMP run.
The shakedown run generated 315 g/L wet weight of cells providing
0.91 g/L 5P12-RANTES in a total of 91.8 L culture supernatant, and
the cGMP run generated 218 g/L wet weight of cells, providing and
0.82 g/L 5P12-RANTES in a total of 100.4 L culture supernatant. The
lower yields of wet cell weight and volumetric productivity of
5P12-RANTES compared to the 19 L scale fermentation are due
adoption of an induction fermentation time of 72 h rather than
96 h. This change was introduced because significant levels of
degradation products began to accumulate after 72 h under the
fermentation conditions used at the 150 L scale.
3.3.5. Downstream processing
Downstream processing at the 19 L scale following the steps
outlined in Fig. 5 provided 3.5 g 96.7% pure 5P12-RANTES, repre-
senting an overall yield of 33%. At the 150 L scale, downstream
processing provided 24.7 g of 96% pure 5P12-RANTES (overall yield
of 28.8%) in the shakedown run, and 27.9 g of 96% pure 5P12-
RANTES (overall yield of 30.9%) in the cGMP run. The purification
yields obtained at each key step are shown in Tables 3e5.
3.4. The cGMP compliant process yields clinical grade material
The 19 L engineering run and the two scaled-up processes
yielded material that meets standards for clinical grade recombi-
nant protein. A summary of the criteria tested and the results ob-
tained are shown in Table 6. Final RP-HPLC (purity) profiles for each
run are highly comparable (Fig. 6). Intact mass spectrometric
analysis (unpublished results) indicated that all the detectable
contaminants are 5P12-RANTES congeners (peak areas ranging
from 0.2% to 2.3%). As expected from the lab scale purificationwork,
these congeners included permutations carrying one or two
oxidized methionine residues and residual uncyclized N-terminal
glutamine. In addition, we identified a deamidated species and a
truncated variant lacking the C-terminal serine residue of the
protein. The major contaminating peak corresponds to intact, N-
terminal glutamine-cyclized 5P12-RANTES carrying a single
oxidized methionine residue.
4. Discussion and conclusions
4.1. An unusual challenge for manufacturing a biopharmaceutical
product
Like many biologics, 5P12-RANTES has an in vitro potency in the
low pM range [7], but unlike most its mode of administration is by
topical application of a gel formulation to genital and othermucosal
surfaces. It has been established for a number of topically applied
inhibitors that block HIV at or soon after the entry stages that full
efficacy in vivo requires concentrations many orders of magnitude
higher than the in vitro IC50 [5,25e28]. We therefore chose 8mg/mL
(approx. 1 mM, close to the solubility limit of the protein) as the
Fig. 5. Outline of scaled-up cGMP-compliant process to produce clinical grade
recombinant 5P12-RANTES. Flow diagram indicating key steps in upstream (orange)
and downstream (blue) processes. (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
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working concentration of 5P12-RANTES for topical use [11]. The
conventional dose volume for such indications is 4 mL of gel, i.e.
32 mg/dose per protected sex act. Assuming an average of 80 sex
acts per person per year [29], the annual requirement per person
would be approximately 2.5 g, i.e. 2.5 tonnes per million people.
While the economics of the development and sale of biologics has
been shaped by historical and market forces acting on injectables,
for topical agents, production could in principle be adapted to the
multi-tonne scale and the low-cost constraints more familiar in the
food and detergent industries.
4.2. Our procedure has the potential to meet manufacturing
requirements
P. pastoris is a well-established expression platform used in the
production of both biopharmaceuticals and industrial proteins
[30,31]. The P. pastoris approach that we present represents a
promising first step towards levels of low-cost, high yield produc-
tion that would be required to meet the worldwide need for use in
topical HIV prevention. All stages of the process conform to the
requirement that they should be scalable, not consume prohibitive
Table 3
Yields recovered at each key step of the downstream process for the 19 L scale engineering run.
Step 5P12-RANTES (initial), g 5P12-RANTES (final), g Step yield (%) Cumulative yield (%)
Harvest 10.11 9.18 90.8 90.8
Butyl 650 M 9.18 10.9 118 107
Capto MMC 10.9 10.9 100.5 108.0
Concn/diafiltration 10.9 9.47 86.7 93.7
Cyclization (N-term. Gln) 9.47 9.84 104 97.4
CHT type I 8.40 4.98 59.3 49.3
Concn/diafiltration 4.98 3.60 72.2 35.6
Final Bulking 3.55 3.47 97.6 34.3
Table 4
Yields recovered at each key step of the downstream process for the 150 L scale shakedown run. ND; not determined, NA; Not Available.
Step 5P12-RANTES (initial), g 5P12-RANTES (final), g Step yield (%) Cumulative yield (%)
Harvest 83.48 94.60 113.3 113.3
Butyl 650 M 94.60 ND NA NA
Capto MMC ND 91.04 NA NA
Conc/Diafiltration 91.04 79.96 87.8 95.6
Cyclization (N-term. Gln) 79.96 81.53 102.0 97.7
CHT type I 81.53 29.01 35.6 34.8
Conc/Diafiltration 29.01 25.54 88.0 30.6
Final Bulking 25.27 24.68 97.7 29.6
Table 5
Yields recovered at each key step of the downstream process for the 150 L scale cGMP run. ND; not determined, NA; Not Available.
Step 5P12-RANTES (initial), g 5P12-RANTES (final), g Step yield (%) Cumulative yield (%)
Harvest 82.26 95.65 116.3 116.3
Butyl 650 M 95.65 ND NA NA
Capto MMC ND 94.73 NA NA
Conc/Diafiltration 94.73 81.70 86.2 99.3
Cyclization (N-term. Gln) 81.70 82.58 101.1 100.4
CHT type I 82.58 31.53 38.2 38.3
Conc/Diafiltration 31.53 27.89 88.5 33.9
Final Bulking 27.89 27.87 99.9 33.9
Table 6
5P12-RANTES produced at 19 L and 150 L meets clinical grade criteria. A series of release assays were performed on final material. Target results and data obtained for each
run are shown.
Criterion Assay Target result Engineering run (19 L) Shakedown run (150 L) cGMP run (150 L)
Concentration SCX-HPLC 8.5 ± 0.3 mg/mL 8.3 mg/mL 8.3 mg/mL 8.6 mg/mL
Purity RP-HPLC 95% purity 97% 96% 96%
Aggregation SEC-HPLC >95% monomer 100% monomer 100% monomer 100% monomer
Identity SDS-PAGE Migration distance conforms to that
of the reference standard
Conforms Conforms Conforms
Western blot Conforms Conforms Conforms
Potency Anti-HIV activity Observed IC50 within 70e130%
of reference standard
75% 97.5% 92%
Filter/plate Bioburden <10 CFU/mL 2 CFU/mL 0 CFU/mL 0 CFU/mL
Endotoxin LAL 65 EU/mL 33.9 EU/mL 7.96 EU/mL 0.36 EU/mL
Host cell protein ELISA Report value 110 ng/mL 200 ng/mL 245 ng/mL
Host cell DNA qPCR Report value ND 1 pg/mg protein 1.5 pg/mg protein
pH pH 3.8, <5.0 4.7 4.8 4.6
Conductivity Conductivity Report value 0.84 mS/cm 0.80 mS/cm 0.85 mS/cm
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quantities of highly expensive materials, nor generate waste
products that carry an environmental hazard. Here we obtained
multi-gram quantities of cGMP-compliant clinical grade material
from a 150 L fermentation, which is more than sufficient for a phase
1 trial. Significant economies of scale will be achievable, and there
is scope for the enhancement of volumetric productivity of the
producer strain, for example by optimizing fermentation condi-
tions to avoid the accumulation of degradation products that
occurred after 72 h at the 150 L scale, increasing transgene copy
number [32], co-expressing chaperones to facilitate protein folding
and secretion [33], or using a combination of the increased copy
number and chaperone co-expression approaches [34].
4.3. Properties of 5P12-RANTES in relation to production and
purification
Several previous studies have shown that chemokines are
readily produced by secretory expression in yeast [14e18], and in
this study we provide another example with 5P12-RANTES. We
took advantage of two particular properties of 5P12-RANTES in the
chosen process: its high temperature stability made it possible to
carry out the cyclization of the N-terminal glutamine residue at
60 C and its high pI was exploited to facilitate downstream pro-
cessing. The N-terminal cyclization is an unusual step to find in a
downstream processing scheme but is mandated by the fact that
the anti-HIV potency of this class of proteins depends on the
absence of a positive charge at the N-terminus [6e8].
4.4. A step towards improving access to biologics
In addition to 5P12-RANTES, several other protein-based drugs
are being considered for development as topical HIV prevention
agents [35,36], and the economic necessities involved have pro-
vided an incentive for researchers to explore methodologies to
produce biologics at lower cost, either by adopting a low cost mi-
crobial fermentation approach as in this study, or through opti-
mized production in transgenic plants [36e38]. Progress made in
these endeavors has the potential be of benefit not only to those at
risk of HIV/AIDS, but also to other patient populations in resource
poor settings that currently lack access to biologics. Greater equity
of access to biologics worldwide is a declared goal of the United
Nations' World Health Assembly [39].
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